- Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
- Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
- Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
More ▼
Key statistics
On Wednesday, Alterity Therapeutics Ltd (ATHE:NAQ) closed at 1.82, 17.10% above the 52 week low of 1.55 set on Feb 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.79 |
---|---|
High | 1.83 |
Low | 1.77 |
Bid | 1.77 |
Offer | 1.90 |
Previous close | 1.81 |
Average volume | 11.42k |
---|---|
Shares outstanding | 8.74m |
Free float | 8.70m |
P/E (TTM) | -- |
Market cap | 13.99m USD |
EPS (TTM) | -1.98 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:49 BST.
More ▼